Encompass Healths home health unit attracts acquisition interestsources

Encompass, which provides post-acute healthcare services, said in October that it planned to spin off the business, called Enhabit, in the first half of 2022. Svea Herbst-Bayliss Private equity firms including Advent International and companies including Aveanna Healthcare Holdings Inc have expressed interest in acquiring the home health and hospice business of Encompass Health Corp , people familiar with the matter said. Encompass, which provides post-acute healthcare services, said in October that it planned to spin off the business, called Enhabit, in the first half of 2022. Last month the Birmingham, Alabama-based company said it was open to the The sources said Enhabit could be worth as much as $3 billion in a sale. Aveanna provides pediatric and adult healthcare services including rehabilitation and hospice services and has a market capitalization of $745 million. Were it to press on with a bid, it would likely need financial backing of top shareholders, including private equity firm Bain Capital. Representatives for Encompass, Advent and Aveanna did not return calls and emails seeking comment. A representative for Bain declined to comment. A shortage of nurses has prompted many players in the U.S. home care sector to try to bulk up or exit. The regulatory environment for mergers in this space has been tough, however. Aveanna abandoned its $1.2 billion acquisition of Maxim Healthcare in 2020 after the Federal Trade Commission objected to the deal. Encompass would not need antitrust clearance if it spun off Enhabit to its shareholders or sold it to a private equity firm that does not own a competing business. Last year hedge fund Jana Partners pushed Encompass, which has a market value of $6.7 billion, to engage with third parties on a potential merger for Enhabit, which offers skilled nursing, aide and homemaker services and occupational therapy. ndustry player would better position the company to manage more challenging conditions in the healthcare industry. Encompass said last month that it would slim down its board to no more than 12 directors after discussions with stockholders, including Jana Partners.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!